top of page

Search

Jul 6, 2021

Promethean BioPharma supports the rescheduling of psilocybin and MDMA in Australia

Updated: Mar 8, 2022

Promethean BioPharma supports the work of Mind Medicine Australia and encourages their submissions to the Therapeutic Goods Administration in relation to the rescheduling of psilocybin and MDMA from Schedule 9 to Schedule 8.

For more information:

https://mindmedicineaustralia.org.au/

https://mindmedicineaustralia.org.au/wp-content/uploads/Mind-Medicine-Australia-Invitation-for-Rescheduling-Guide-27-August-2020.pdf

https://mindmedicineaustralia.org.au/wp-content/uploads/Mind-Medicine-Australia-Fact-Sheet-22-February-2021.pdf

Recent Posts

Cannabis Pill Trial

A world-first cannabis pill is being trialled that could bring relief to millions of people living with chronic pain. If successful,...

Australia Pioneers World’s First CBD Pill for Chronic Pain Relief in Groundbreaking Trial

In a groundbreaking initiative, Australia is set to lead the world in the development of a revolutionary cannabis pill designed to bring...

Promethean BioPharma joins over-the-counter CBD race

Promethean BioPharma joins over-the-counter CBD race to register a Schedule 3, over-the-counter CBD medicine with a clinical trial of...

Comments

bottom of page